source
- Biogen's tau-targeting Alzheimer's drug shows cognitive slowing in mid-stage trialBiogen reported results from its mid-stage "Celia" trial testing the experimental tau-targeting antibody BIIB080 in patients with early Alzheimer's disease. The study compared three dose levels of…
- AstraZeneca to acquire worldwide rights to Dizal's lung cancer drug Zegfrovy for $600 millionAstraZeneca announced it will pay $600 million upfront to Dizal Pharmaceutical for the worldwide development and sales rights to the lung cancer drug Zegfrovy. The agreement gives AstraZeneca full…